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Abstract
Nucleic acid testing (NAT) for malaria parasites is an increasingly recommended diagnostic endpoint in clinical trials of
vaccine and drug candidates and is also important in surveillance of malaria control and elimination efforts. A variety of
reported NAT assays have been described, yet no formal external quality assurance (EQA) program provides validation for
the assays in use. Here, we report results of an EQA exercise for malaria NAT assays. Among five centers conducting
controlled human malaria infection trials, all centers achieved 100% specificity and demonstrated limits of detection
consistent with each laboratory’s pre-stated expectations. Quantitative bias of reported results compared to expected
results was generally ,0.5 log10 parasites/mL except for one laboratory where the EQA effort identified likely reasons for a
general quantitative shift. The within-laboratory variation for all assays was low at ,10% coefficient of variation across a
range of parasite densities. Based on this study, we propose to create a Molecular Malaria Quality Assessment program that
fulfills the need for EQA of malaria NAT assays worldwide.
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Introduction
During the past two decades, numerous nucleic acid testing
(NAT) approaches for the diagnosis of human malaria infection
have been developed [1–21]. NAT can detect and quantify
parasites more sensitively and precisely than by microscopy or
rapid diagnostic tests (RDTs). NAT approaches are valuable for
controlled human malaria infection (CHMI) studies of investiga-
tional drug and vaccine candidates, for drug efficacy studies and
for epidemiological surveillance [22]. In CHMI studies for
example, healthy human volunteers are infected via the bites of
Plasmodium falciparum-infected mosquitoes [23–25] or by needle-
based delivery of purified sporozoites [26,27]. CHMI is used in
initial efficacy studies of investigational drugs and vaccines because
of its reproducibility and convenience as compared with efficacy
studies in malaria-endemic populations that require larger studies
and rely on natural exposure [26,28–40]. NAT assays allow for
quantitative measurement of peripheral parasitemia up to 2–6
days earlier than microscopy [26,27,30,41], further improving the
safety of this already very safe model. Depending on the trial
design and the laboratory capabilities, samples can be tested either
in real time using fresh samples or retrospectively using archived
samples. NAT is less operator-dependent and more amenable to
high throughput testing than microscopy but is more expensive.
The increased cost of NA testing in clinical trials affords improved
discrimination between infected and uninfected subjects (e.g.,
fewer false positives and false negatives) and production of
quantitative datasets that can be used for modeling parasite
growth. In addition, because earlier detection and therefore earlier
treatment of asymptomatic parasitemia decreases both volunteer
risk and discomfort, use of NAT assays can facilitate the
elimination of the costly but traditional ‘hotel’ phase of many
studies where volunteers are housed near study staff for close
monitoring. The many advantages and disadvantages of micros-
copy, RDTs and NAT vary depending on whether the result is
used for monitoring of clinical trials, for clinical care in endemic or
non-endemic settings or for epidemiological surveillance, as
recently reviewed [22].
When testing is performed on the day of collection, NAT results
are used in some centers alongside clinical assessments and
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microscopic findings to inform treatment decisions. This is useful
since the symptoms of malaria are non-specific and overlap with
common viral illnesses. NAT results can be particularly useful
when these traditional measures like microscopy are inconclusive.
Despite use of highly-trained slide readers, detection of 1–2
parasites on a thin blood smear is neither 100% sensitive nor
specific for the low parasite density capable of causing symptom-
atic malaria. Some CHMI centers have even replaced primary
microscopy-based endpoints with primary NAT endpoints. When
NAT was performed in real time and used to make treatment
decisions, this approach reduced reported clinical symptoms in
CHMI subjects relative to microscopy-based treatment decision
making (G. Bastiaens, unpublished data). Thus, the NAT result
can help eliminate diagnostic uncertainly that may otherwise occur
in subjects who are either ostensibly slide positive or symptomatic
but not both. Overall, real time availability of NAT apparently
helps avoid false positive and false negative diagnoses, thereby
increasing both the safety of the volunteers and the accuracy of the
data. Aside from lower limits of detection (LoD) that afford earlier
diagnoses, quantitative NAT data provide day-by-day measures of
the rise and fall of parasitemia and allow for model-based
assessments of liver-to-blood inocula levels and parasite multipli-
cation rates, which can be used to calculate efficacy estimates for
partially-effective liver vaccines and for blood-stage vaccines
[42,43].
Quality systems are critical to clinical trial and surveillance
networks because the validity of diagnostic and monitoring tests
and the ability to compare trial results amongst network
laboratories is entirely dependent on the procedures used before,
during and after each assay at each site [22]. Consistently
dependable results are provided when the overall program
includes quality control (QC), quality assurance (QA) and
proficiency testing (PT) [44]. Malaria QA systems have been
developed to address the wide performance variations observed in
first generation RDTs [45]. These efforts resulted in consistently
improved RDT performance with each successive round of
evaluations and led to elimination of poor RDT products.
External QA (EQA) programs and control reagents for RDTs
are also emerging [46–48]. Terminology related to quality
management and assay performance is defined in the Glossary
section.
Because of the availability of cryopreserved metabolically-active,
non-replicating sporozoites [49] and the renewed vigor of vaccine
and drug pipelines, CHMI studies are now being conducted at an
increasing number of institutions worldwide [50]. However, while
consensus procedures for CHMI studies and microscopy are
available [51], no such effort has been made to standardize
malaria NAT assays or provide widespread ongoing EQA
oversight. Some laboratories have exchanged small panels of
malaria-infected whole blood with collaborators as part of NAT
assay validation (S. Murphy, C. Hermsen, N. Edwards, A.
Stewart, unpublished data). In addition, the World Health
Organization (WHO) previously generated freeze-dried P. falci-
parum-infected blood samples at a single high parasitemia level for
use as an international DNA standard [52]. Some laboratories are
using the WHO material (for example see reference [53]), but the
WHO material is not provided through a formal EQA program.
Because the material was freeze-dried from whole blood without
buffers or steps to protect RNA, it also cannot be used to support
RNA-based assays, and the freeze-dried material does not
precisely mimic material obtained from clinical trial participants.
Therefore, a formalized, funded program is needed to ensure assay
validation and provide malaria NAT EQA in line with that
commonly used for assays detecting HIV and other infectious
pathogens [54–56]. As a trial EQA platform, we sent blinded
specimens to five malaria centers conducting CHMI studies. Here,
we report the results of this exercise and propose a framework for
ongoing EQA and eventually for assay harmonization.
Materials and Methods
Malaria culture and production of samples
P. falciparum strain 3D7 was cultured, synchronized and diluted
as previously reported [41]. For multiply-infected cells, each
parasite was counted in microscopic parasite density measure-
ments. A ring-stage synchronous high parasitemia culture was
diluted into type A+ whole human blood obtained from the Puget
Sound Blood Center (www.psbc.org). After preparing the ‘master’
tube at each density, samples were aliquoted into bar code-labeled
tubes [each bearing a unique specimen identifier generated in the
Laboratory Data Management System (Frontier Science)] and
prepared for frozen storage according to the individual standard
operating procedures for each final testing laboratory. Aliquot
sizes were as follows: RUMC and University of Maryland 0.5 mL;
NIH 0.2 mL into 2 mL NucliSENS lysis buffer (bioMe´rieux);
University of Washington (UW) 0.05 mL into 2 mL NucliSENS
lysis buffer; Oxford filtered to remove leukocytes as described [57]
and aliquoted as 0.5 mL volumes. Once aliquoted, all samples
were frozen at 280uC before courier shipments to partner
laboratories on dry ice.
Sample testing
Laboratories received and stored samples at #270uC before
testing. Each lab except for the NIH received 10 de-identified
parasite-containing samples at each of five different concentrations
plus 10 parasite-negative samples; the NIH received 20 samples at
each level. Labs were blinded to the parasite concentration in each
sample. Each laboratory tested their designated samples according
to the laboratory-specific standard operating procedure (SOP) and
reported data to the UW coordinating center. Testing laboratories
(including the technologists at the UW coordinating laboratory)
were blinded to the nominal parasite density of each sample.
Assays used included P. falciparum quantitative reverse transcrip-
tion polymerase chain reaction (qRT-PCR; UW, [58]); quantita-
tive PCR (qPCR; RUMC, [21,59]; Oxford [26]; University of
Maryland [35,37]) and standard PCR (NIH [34]). If known,
laboratories indicated their in-house determined limits of detection
(LoD) and nucleic acid target characteristics (Table 1). All
laboratories reported quantitative data, except the NIH which
reported qualitative results and cycle thresholds (CT) from
standard PCR. Each laboratory was asked to run the assay and
provide data strictly in accordance with the SOP used in their
clinical trials.
Filtration studies (Oxford only)
Ring-stage cultured 3D7 strain P. falciparum parasites were
added to leukocyte-depleted [26] whole blood. Each sample was
subsequently divided and half of the material at each density was
subjected to Whatman VFE filtration while half remained
unfiltered. The material was then subjected to DNA extraction
and qPCR by the standard Oxford protocol [26].
Calibrator matrix studies (Oxford only)
DNA was extracted from blood from malaria-negative volun-
teers using the standard Oxford protocol [26] to generate ‘negative
blood matrix’ samples. qPCR was performed on 150 copies of the
Oxford plasmid DNA calibrator in the presence of a blood matrix
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sample or a water control (20% v/v) and differences in the CT and
quantity were evaluated.
Data analysis
Data were transformed to log10 parasites/mL of whole blood
and analyzed using Excel 2010 (Microsoft) and Prism 6
(GraphPad). Intra-laboratory performance was evaluated using
sensitivity/specificity analyses, precision analyses and Bland-Alt-
man (difference) plots. The lowest parasite density samples
(6 parasites/mL) were not included in statistical analyses. Data
were plotted on a log10 parasites/mL scale; data from the NIH was
regressed to the nominal values of the provided samples and
plotted for illustration purposes. For precision studies, the percent
coefficient of variation was calculated as %CV = standard
deviation/mean.
Results
Sample production
A high parasitemia starting culture was prepared to 2.46108
(8.38 log10) parasites/mL based on repeated counts of Giemsa-
stained thin blood smears by multiple readers combined with
determination of RBC density (RBC/mL) by hemocytometer
counting. This material was devoid of trophozoite- and schizont-
stage parasites and contained singly (70%) and multiply-infected
(30%) ring-stage parasites as judged by microscopy. Dilutions were
made into whole blood to nominal parasite densities as follows:
High (300,000 parasites/mL or 5.48 log10 parasites/mL); Mid
(6,000 parasites/mL or 3.78 log10 parasites/mL); Low (600 par-
asites/mL or 2.78 log10 parasites/mL); Very Low (60 parasites/
mL or 1.78 log10 parasites/mL), Trace (6 parasites/mL or
0.78 log10 parasites/mL) and Negative (no parasites); these
Figure 1. Study data. Results were plotted on a log10 parasites/mL
scale for the five participating laboratories; bars show the mean and
95% confidence interval. Nominal (expected) values for all samples are
plotted as follows: high (300,000 parasites/mL or 5.48 log10 parasites/
mL); mid (6,000 parasites/mL or 3.78 log10 parasites/mL); low (600 par-
asites/mL or 2.78 log10 parasites/mL); very low (60 parasites/mL or
1.78 log10 parasites/mL), trace (6 parasites/mL or 0.78 log10 parasites/
mL) and negative (no parasites). Samples with no parasites detected
were plotted as 0.1 log10 parasites/mL. Two-way ANOVA comparisons
across all high, mid and low parasite density samples with quantita-
tively positive results showed non-statistically significant differences
amongst all groups (p.0.05) except for RUMC vs. Oxford at high (p,
0.0001), mid (p,0.01) and low (p#0.05) parasite densities. *NIH
quantities were generated by regression of CT values to expected
EQA values and are provided to visualize variation and qualitative
agreement; quantitative statistical comparisons were not included. 60
of 120 representative NIH samples are displayed for consistency.
doi:10.1371/journal.pone.0097398.g001
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designations are used throughout the paper to refer to these
specific parasite densities.
Network laboratory results
Laboratories reported the results shown in the Figure 1. The
sensitivity and specificity of each laboratory’s assay was calculated
based on the negative control samples plus either all samples $
60 parasites/mL or those $600 parasites/mL; samples at 6 par-
asites/mL were not included in these analyses since this ultra-low
level of parasite density was below the stated LoD for all assays
(Table 2). All laboratories demonstrated 100% specificity. Most
laboratories detected all samples at $600 parasites/mL, although
the University of Maryland reported one false negative at this
level.
Analytical sensitivity was below 100% at the 60 parasites/mL
level: UW detected 6/10 samples, Oxford 4/10, NIH 6/20,
Maryland 4/10 and RUMC 2/10. One positive sample was
detected by the UW laboratory amongst the 6 parasites/mL
samples at a concentration consistent with the presence of a single
parasite in the sample and consistent with the overall frequency of
positives at the 60 parasites/mL level as well. The ‘trace’
(6 parasites/mL) specimens were not included in estimates of
sensitivity and specificity because they cannot be categorically
considered positive for the following assay-specific reasons. For the
low volume RT-PCR assay at UW, most of these samples are
negative because a density of 6 parasites/mL equates to less than
one parasite per sample on average. Nonetheless, when samples at
this level are positive by RT-PCR due to an intact parasite, the
parasite contains ,3500 copies of the targeted 18S rRNA. For
higher volume DNA assays, the lack of positive results at the
6 parasites/mL level reflects a combination of similar Poisson
distribution limitations (e.g., 6 parasites/mL is an average of
1.2 parasites/sample for 200 mL samples or 3 parasites/sample for
500 mL samples) as well as limitations on PCR performance at low
copy numbers (e.g., 2–10 DNA copies/sample). Thus, the virtual
absence of positive results in samples at 6 parasites/mL was
expected, indicates that positive results are due to intact parasites
and not free template and supports the high specificity shown by
all laboratories. False negative results at the 60 parasites/mL level
can be attributed to the presence of multiply-infected RBCs that
result in a more heterogeneous distribution of parasites upon
dilution to low parasitemia than would be expected if virtually no
multiply-infected cells were present. A related type of heteroge-
neity has also reported for malaria microscopy – in thick blood
smears, malaria parasites are sometimes unevenly distributed
(known as ‘grouping’) [60]. At low parasite densities, grouping
results in a few microscopic fields containing more parasites than
expected while most fields contain fewer or zero parasites, leading
to overdispersion of the Poisson distribution [61]. Much like
‘grouping’ in thick blood smears, multiply-infected cells contain a
larger-than-expected proportion of the NAT target(s), thereby
altering the frequency of parasite-containing samples at low
parasitemias. Nonetheless, the overall data indicate agreement
between laboratories across a wide range of parasite densities, with
gradual loss of positivity as predicted by assay LoDs.
Differences from the expected values (quantitative bias) were
assessed using correlation and Bland-Altman (difference) plots,
which are summarized in Table 3. In general, all assays behaved
linearly (slope ,1.0 and r2.0.9), indicating comparable template
amplification efficiencies. The average quantitative bias across all
laboratories was ,60.18 log10 parasites/mL compared to ex-
pected values, with the exception of the Oxford qPCR. In
addition, most laboratories maintained a 95% confidence range
within 60.5 log10 parasites/mL compared to the expected values
with the exception of Maryland whose assay had lower limit of the
95% confidence interval extending to 20.66 log10 parasites/mL.
The Oxford qPCR showed an average difference of 20.54 log10
parasites/mL (95%CI 20.90 to 20.19 log10 parasites/mL),
thereby underestimating relative to expected values and other
laboratories. This difference was consistent across the range of
parasite densities for Oxford and the confidence interval for the
Oxford qPCR was within 60.5 log10 parasites/mL of the average
Oxford values.
Precision (%CV) was evaluated for each laboratory’s assay for
the high, mid and low parasite density samples (Table 4). As
expected, the highest parasite density samples showed the lowest
degree of variation and, with the exception of the Maryland
qPCR, the lowest parasite density samples had the highest
variation. Variation was generally ,10%CV at all levels. This
level of precision is considered acceptable by most validation
criteria and is likely to be more than adequate for purposes of
modeling parasite growth dynamics [42,43]. Very low parasite
density samples were not included in this analysis because of the
smaller number of positive samples.
Root cause analyses of differences
Two of the network groups further investigated apparently
aberrant results to determine if the root cause could be identified.
Table 3. Correlation and agreement between assay-derived data and expected values.
Correlationa Agreementb
Laboratory Slope r2 Quantitative bias (95% confidence interval) nc
UW 1.04 0.98 20.05 (20.39–0.29) 37
Oxford 1.00 0.98 20.54 (20.90–20.19) 34
NIHd 0.97 0.97 0.13 (20.30–0.55) 66
RUMC 0.90 0.99 0.1 (20.29–0.48) 32
Maryland 0.99 0.96 20.18 (20.66–0.31) 35
aEach laboratory’s assay-derived data were plotted against the expected values, and the slope (D assay-derived value/D expected value) and coefficient of
determination (r2) were calculated using Microsoft Excel. A slope of 1.0 and r2 value of 1.0 indicates perfect correlation.
bBland-Altman difference plots were used to calculate the mean quantitative bias as the mean of the differences between each reported value and its expected value.
Values are in log10 parasites/mL. An absolute value of #0.5 log10 parasites/mL indicates an absence of quantitative bias.
cAll calculations were based on all NAT-positive samples.
dNIH quantities were generated by regression of CT values to nominal values and should be viewed as a measure of variation only.
doi:10.1371/journal.pone.0097398.t003
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The single false negative 600 parasites/mL sample at the
University of Maryland was found to be qualitatively positive,
but at a concentration below the quantitative LoD established for
that assay. Root cause analysis showed that the DNA extraction
control used to monitor extraction efficiency was lower than the
expected value, indicating that poor sample extraction was at fault
- re-extraction of the specific sample was not possible since the
material was completely consumed in the initial testing.
Additional studies were conducted by Oxford University to
estimate the contribution of blood filtering and calibrator matrix
differences to the observed quantitative shift. To test the
hypothesis that parasites may be lost during blood filtration,
parasites diluted in pre-leukocyte-depleted blood were tested by
Oxford qPCR either with or without filtration. Filtration reduced
the measured parasite density by 13–57% (20.06 to 20.37 log10-
fold) (Figure S1). To determine if the matrix used to dilute the
plasmid DNA calibrators at Oxford also contributed to the
quantitative shift, DNA extracted from malaria-negative volun-
teers was used in lieu of water to dilute the plasmid DNA
calibrator in the qPCR reaction. One-hundred fifty copies of
plasmid DNA were added since this corresponds to the amount of
plasmid DNA equal to 1000 parasites/mL by the Oxford qPCR
assay. In the presence of the negative blood matrix, the Oxford
qPCR CT was delayed by a median of 1.1 cycles as compared to
the previously used water matrix – this difference was consistently
observed using blood from three different donors (range 1.1–1.4
cycles) (Figure S1). This CT shift corresponds to a 58–65%
reduction in the apparent parasite density (median 20.39 log10-
fold, range 20.37 to 20.46 log10-fold) relative to amplification
using a water-only diluent reduction (Figure S1).
Discussion
This study represents the first major malaria NAT EQA
exercise to our knowledge amongst CHMI centers providing
assay-to-assay comparisons that attempt to fully account for all
variables contributing to assay performance. The data indicate
that CHMI centers listed here are reporting comparable results.
CHMI studies seek to ensure the safety of the trial participants and
the integrity of the trial data. In this regard, all centers achieved
expected analytical sensitivities based on known LoDs. Based on
clinical trial data and supported by modeling studies [41–43], the
assays compared here are likely to become positive before patent
parasitemia develops following CHMI with five mosquito bites. No
false positive results were reported for any of the 10–20 blinded
malaria-negative samples sent to each laboratory. Quantitative
variation was ,10%CV amongst the high, mid and low parasite
density samples. The average quantitative bias across all labora-
tories was ,60.18 log10 parasites/mL compared to expected
values, and all laboratories except for Oxford showed a 95%
confidence range within60.5 log10 parasites/mL compared to the
expected values.
The Oxford assay was highly sensitive, specific and precise, but
was quantitatively shifted compared to other assays and to
expected results. As described in the Results, additional studies
conducted by Oxford University determined that both parasite
losses due to Whatman VFE filtering of whole blood and
differences in the matrix used for plasmid DNA calibrators at
Oxford contributed to this shift. This is the first report to our
knowledge that demonstrates parasite losses due to the filtering
step. This step was added at Oxford to remove co-purified
leukocyte genomic DNA (gDNA), which may inhibit some PCR
assays [62]. Thus, while filtration removes inhibitors like gDNA, it
also removes parasites. In addition, the Oxford plasmid calibrators
are normally diluted in a water matrix, which lacks additional
PCR inhibitors common to whole blood extractions (e.g.,
immunoglobulin G, hemoglobin and lactoferrin [63,64]). Since
the water-diluted plasmid calibrator was detected earlier than
when diluted in a whole blood matrix, it appears that PCR
inhibitors present in the eluates obtained from blood delay PCR
target amplification and also contribute to the quantitative
reduction in parasites when a water-diluted standard curve was
used. This type of matrix effect has been reported in biological
samples [65]. Despite the shift in absolute quantitation, relative
quantitation between samples using the Oxford assay was
comparable to that of other centers. The Oxford qPCR is
reporting positive and negative results in complete agreement with
other laboratories, even at the low 60 parasites/mL level
suggesting that the combined effects of blood filtration and the
different calibrator matrix did not markedly change the overall
qualitative results. Nonetheless, re-calibration of the Oxford qPCR
method that will account for these differences is underway. This
EQA effort helped to identify an easily fixed methodological
difference in calibration that may account for differences in
absolute quantification, and work is underway at Oxford to rectify
this shift. Overall, the results of most laboratories were within the
expected quantitative range, and these findings should be
reassuring to vaccine and drug makers, sponsors and regulators
as NAT gradually replaces microscopy for safety and efficacy
endpoints.
With the plethora of malaria NAT methods reported in the
literature, quality indicators are needed to help select and maintain
methods suitable for use in CHMI studies. However, malaria NAT
EQA and consensus malaria NAT guidelines do not yet exist in
part because over 65 different assays have been reported for NAT-
based malaria diagnosis. The literature includes many variations
on extraction, amplification and detection, including single-step
Table 4. Precision statistics by laboratory.
High (300,000 parasites/mL) Mid (6,000 parasites/mL) Low (600 parasites/mL)
Laboratory %CV n %CV n %CV n
UW 1.5 10 1.6 10 5.3 10
Oxford 3.5 10 3.3 10 7.1 10
NIHa 1.7 20 2.6 20 10.0 20
RUMC 0.9 10 4.5 10 6.9 10
Maryland 3.4 10 11.1 10 5.1 9
aNIH quantities were generated by regression of CT values to nominal values and should be viewed as a measure of variation only.
doi:10.1371/journal.pone.0097398.t004
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and nested electrophoresis-based PCR, qPCR, qRT-PCR and
nucleic acid-based sequence amplification (NASBA) with an even
wider variety of reported primer and probe combinations (briefly
reviewed in [22]). Additional novel assays continue to be
developed, including potentially field-friendly approaches such as
loop-mediated isothermal amplification [66]. While numerous
other gene targets are reported, the most widely used Plasmodium
NAT targets are sequences within the developmentally-regulated
18S rRNAs (by RT-PCR or NASBA) or their coding genes (by
PCR) [67]. However, 18S rRNAs and their corresponding coding
genes are not uniformly captured by a single set of reagents
(primers and probe), and assay design can greatly alter sensitivity
and specificity as recently reviewed [22]. RT-PCR tests target A-
type (asexual stage) 18S rRNAs to take advantage of the fact that
A-type (but not sexual-stage S-type) 18S rRNAs are biologically
amplified to ,3500 copies per ring-stage parasite during the red
blood cell stage of infection [41]. PCR tests can target any of the
18S rRNA-coding genes, and some primers and/or probes are
designed to capture sequences shared by more than one of the
genes (up to five including one pseudogene) thereby incrementally
increasing assay sensitivity. Thus, RT-PCR assays become positive
earlier in the amplification process (lower cycle threshold)
compared to PCR, and this can improve RT-PCR sensitivity
particularly with small sample volumes and/or extremely low
parasite densities (S. Murphy, unpublished data). While rRNA
copies are more abundant than the parent genes, samples for RT-
PCR must be preserved by adding a stabilizing buffer or by
making dried blood spots at the time of collection [58], whereas
samples for PCR can be simply frozen. These aspects of malaria
NAT have mostly been studied using laboratory strains of P.
falciparum, and future work will need to address assays designed to
test for other human Plasmodium spp. since species and sub-species
diversity in field settings affects assay performance [68,69].
Thus, because of the diversity of pre-analytical processing,
extraction and amplification techniques, a single EQA sample type
cannot currently be used in all assays. EQA efforts must therefore
account for these methodological variations in pre-analytical
(collection, stabilization) and analytical (extraction, amplification)
steps.
To support clinical trials using malaria NAT, a formal EQA
program is needed. Some previous efforts have been made to
improve the quality of malaria NAT, although none provide
formal EQA. As mentioned above, the WHO previously
developed and distributed its single concentration standard to
many laboratories for characterization purposes [52], however,
this standard is unsuitable for RNA-based assays and does not
precisely mimic clinical samples. Another group compared PCR
primers and probes used by several centers but it was not possible
for the investigators to perform all the pre-analytical, analytical
(extraction, amplification and detection) and post-analytical steps
for each assay as originally described and therefore the study did
not assess overall assay performance [53]. Most recently, a study of
field samples in Brazil compared two conventional PCR methods
against microscopy and concluded that the PCR protocols showed
low reproducibility at sub-microscopic densities [70]. In contrast,
the groups tested in our EQA study generated reproducible data at
sub-microscopic densities (e.g., 600 parasites/mL), but our study
was performed using laboratory-generated samples so this may
change when field samples are used. True EQA comparisons, such
as the work described herein, are needed to fully account for all
factors that lead to assay variability and ensure that high quality
assays are in place to support clinical and field studies.
To continue our work and fulfill the need for an ongoing EQA
program, we propose creation of the Molecular Malaria Quality
Assessment (MolMalQA) Program as a multi-lateral effort
involving one or more core reference laboratories and a larger
network of partner laboratories at centers performing malaria
clinical trials, drug efficacy testing and surveillance activities. The
core laboratories would provide malaria EQA samples, produce
an international calibrator suitable for use in DNA and RNA
assays and pursue harmonization activities in consultation with
network partners. The malaria effort will be somewhat more
complicated than EQA programs for many viral pathogens
because of the complexity of the parasite lifecycle and the diversity
of available tests. At a minimum, it will be necessary to provide
EQA samples for DNA- and RNA-based assays alike and to
support both liquid and dried blood spot formats. For global EQA,
we propose to use synchronized, cultured ring-stage malaria
parasites diluted into whole blood since this mimics clinical
samples. The EQA program will need to develop whole blood
panels derived from a spectrum of healthy human subjects with
diverse blood types to ensure that results are not skewed by a single
blood source. In future, gametocytes, the sexual malaria stage
parasite found in humans, can be provided as EQA samples if
needed. The EQA program can also undertake stability studies to
assess the collection, transport and long-term storage stability of
samples intended for malaria DNA and RNA testing to determine
if the relatively greater stability of DNA outweighs the increased
abundance of RNA for use in large field studies.
Eventually, assays in use should also be harmonized around a
single or very few high-quality diagnostic protocols. Selection of
such assays could be made by reviewing EQA data and studying
protocols and instrument requirements in consultation with the
network of CHMI centers.
In addition to ensuring valid diagnostic data in clinical trials, an
EQA program would also aid in NAT surveillance for the malaria
elimination/eradication agenda. The relevance of malaria NAT
EQA for surveillance efforts should not be overlooked because
global success in reducing malaria incidence will reach a point at
which control and eradication decisions will require monitoring of
infection among individuals harboring parasites at densities
beneath the LoD of both microscopy and RDTs [71].
To more closely align quantitative results across centers and
eliminate lot-to-lot variation in cultured parasites, we further
advocate for development of synthetic nucleic acid sequences
diluted in whole blood for use as absolute calibrators. Such
reagents allow determination of exact target copy numbers, which
can be translated to parasite densities by testing parasite-
containing controls against a calibrator standard curve. However,
since the 18S rRNA targets vary between testing centers, no single
naturally-occurring target sequence is shared by all laboratories.
Some centers target the asexual-type 18S rRNAs or the coding
genes while others target the genes encoding the sexual-type 18S
rRNAs. Thus, cloning just one of these genes fails to capture other
laboratories’ targets. Novel synthetic sequences are therefore
needed to provide cross-network calibrators suitable for more than
one assay - such materials are in development (S. Murphy,
unpublished data).
In summary, malaria NAT EQA will help safeguard the
reliability and comparability of data produced in clinical trials by
CHMI centers and will support future extended use of malaria
NATs in other contexts. Through collaboration and with multi-
lateral funding, a formal EQA program can be developed and
implemented worldwide for the benefit of the malaria field and
those it serves.
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Supporting Information
Figure S1 Parasite loss due to filtering and calibrator
matrix differences contribute to the quantitative shift in
Oxford qPCR. A: Filtration using the Whatman VFE plate
results in loss of parasites. Cultured parasites were combined with
leukocyte-depleted blood and then filtered or not as indicated in
the figure. Results of Oxford qPCR are shown; each point
represents the mean of triplicate PCR wells. B-C: Oxford qPCR in
a whole blood matrix results in delayed CT and lower apparent
parasite density than when a water matrix is used. Eluates from
leukocyte-depleted blood or a water control were added to qPCR
reactions containing 150 copies of a plasmid DNA calibrator.
Panel B depicts CT values. Panel C shows the apparent parasite
density; the horizontal dashed line represents the result in the
presence of water-only diluent (150 plasmid copies/reaction
= 1000 parasites/mL in the Oxford assay by definition). Each
point in B-C represents the result in an individual PCR well.
(TIF)
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